Eli Lilly (LLY) Stock: $20B in Deals and a New Oral GLP-1 — What’s Next?
Eli Lilly's stock has surged this year, bolstered by new drug launches and strong revenue forecasts. The company's recent developments are set to impact its future growth.
Editorial Staff about 5 hours ago